USD
+$0.00
(+0.00%
)At Close (As of Oct 13, 2025)
$1.83B
Market Cap
-
P/E Ratio
-1.54
EPS
$103.81
52 Week High
$32.54
52 Week Low
HEALTHCARE
Sector
Field | Value (USD) |
---|---|
Gross Profit | $137M |
Total Revenue | $224M |
Cost Of Revenue | $87M |
Costof Goods And Services Sold | $87M |
Operating Income | -$97M |
Selling General And Administrative | $171M |
Research And Development | $62M |
Operating Expenses | $234M |
Investment Income Net | - |
Net Interest Income | $6.7M |
Interest Income | $11M |
Interest Expense | $4.2M |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $5.2M |
Income Before Tax | -$91M |
Income Tax Expense | - |
Interest And Debt Expense | - |
Net Income From Continuing Operations | -$91M |
Comprehensive Income Net Of Tax | - |
Ebit | -$87M |
Ebitda | -$82M |
Net Income | -$91M |
Field | Value (USD) |
---|---|
Total Assets | $534M |
Total Current Assets | $482M |
Cash And Cash Equivalents At Carrying Value | $334M |
Cash And Short Term Investments | $334M |
Inventory | $56M |
Current Net Receivables | $83M |
Total Non Current Assets | $52M |
Property Plant Equipment | - |
Accumulated Depreciation Amortization Ppe | - |
Intangible Assets | $932K |
Intangible Assets Excluding Goodwill | $932K |
Goodwill | - |
Investments | - |
Long Term Investments | - |
Short Term Investments | - |
Other Current Assets | $8.5M |
Other Non Current Assets | - |
Total Liabilities | $132M |
Total Current Liabilities | $53M |
Current Accounts Payable | $10M |
Deferred Revenue | - |
Current Debt | - |
Short Term Debt | $1.9M |
Total Non Current Liabilities | $79M |
Capital Lease Obligations | $29M |
Long Term Debt | $51M |
Current Long Term Debt | - |
Long Term Debt Noncurrent | - |
Short Long Term Debt Total | $80M |
Other Current Liabilities | $30M |
Other Non Current Liabilities | $324K |
Total Shareholder Equity | $402M |
Treasury Stock | - |
Retained Earnings | -$546M |
Common Stock | - |
Common Stock Shares Outstanding | $52M |
Field | Value (USD) |
---|---|
Operating Cashflow | -$99M |
Payments For Operating Activities | - |
Proceeds From Operating Activities | - |
Change In Operating Liabilities | - |
Change In Operating Assets | - |
Depreciation Depletion And Amortization | $5.2M |
Capital Expenditures | $4.4M |
Change In Receivables | - |
Change In Inventory | -$17M |
Profit Loss | - |
Cashflow From Investment | -$4.4M |
Cashflow From Financing | $180M |
Proceeds From Repayments Of Short Term Debt | - |
Payments For Repurchase Of Common Stock | - |
Payments For Repurchase Of Equity | - |
Payments For Repurchase Of Preferred Stock | - |
Dividend Payout | - |
Dividend Payout Common Stock | - |
Dividend Payout Preferred Stock | - |
Proceeds From Issuance Of Common Stock | - |
Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
Proceeds From Issuance Of Preferred Stock | - |
Proceeds From Repurchase Of Equity | $4.5M |
Proceeds From Sale Of Treasury Stock | - |
Change In Cash And Cash Equivalents | - |
Change In Exchange Rate | - |
Net Income | -$91M |
Field | Value (USD) |
---|---|
Gross Profit | $137M |
Total Revenue | $224M |
Cost Of Revenue | $87M |
Costof Goods And Services Sold | $87M |
Operating Income | -$97M |
Selling General And Administrative | $171M |
Research And Development | $62M |
Operating Expenses | $234M |
Investment Income Net | - |
Net Interest Income | $6.7M |
Interest Income | $11M |
Interest Expense | $4.2M |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $5.2M |
Income Before Tax | -$91M |
Income Tax Expense | - |
Interest And Debt Expense | - |
Net Income From Continuing Operations | -$91M |
Comprehensive Income Net Of Tax | - |
Ebit | -$87M |
Ebitda | -$82M |
Net Income | -$91M |
Sector: HEALTHCARE
Industry: MEDICAL DEVICES
PROCEPT BioRobotics Corporation (Ticker: PRCT) is an innovative surgical robotics firm based in Redwood City, California, focused on developing advanced solutions for urological procedures. The company's flagship technology leverages robotic-assisted systems to enhance the precision and effectiveness of surgical interventions, thereby improving patient outcomes and operational efficiencies. With a commitment to transforming urology through robotics, PROCEPT aims to position itself as a leader in the medical technology sector, addressing unmet clinical needs and driving growth through innovative product offerings and strategic partnerships.